1 / 4

What we know about investments in hepatitis and the need for new advocacy tools

What we know about investments in hepatitis and the need for new advocacy tools. Chris Taylor, Associate Director, Viral Hepatitis AIDS 2012 – Global Village Session July 23, 2012. The Budget Landscape. Very little funding dedicated to viral hepatitis

ellard
Download Presentation

What we know about investments in hepatitis and the need for new advocacy tools

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. What we know about investments in hepatitis and the need for new advocacy tools Chris Taylor, Associate Director, Viral Hepatitis AIDS 2012 – Global Village Session July 23, 2012

  2. The Budget Landscape • Very little funding dedicated to viral hepatitis • US – CDC Division of Viral Hepatitis ~$30 million • US – NIH ~$100 million • US – Other agencies – very little to no dedicated funding • WHO – very few staff assigned to viral hepatitis • Need greatly outweighs available funding • Relying on public/private partnerships

  3. How You Can Help! • Work with hepatitis advocates in your area • Assist with identifying hepatitis funding while conducting HIV resource tracking • Carry hepatitis advocacy messages • Look at co-infection rates and develop a strategy • Ask like-minded donors to consider hepatitis also • Share your expertise about resource tracking

  4. World Hepatitis Alliance • www.worldhepatitisalliance.org • National Viral Hepatitis Roundtable • www.nvhr.org Chris Taylor Associate Director, Viral Hepatitis 202.434.8090 ctaylor@NASTAD.org

More Related